Resverlogix Corp T.RVX

Alternate Symbol(s): RVXCF

Healthcare Biotechnology

Resverlogix Corp. is a Canada-based late-stage biotechnology company. The Company is engaged in epigenetics, with a focus on developing therapies for the benefit of patients with chronic diseases. Its epigenetic therapies are designed to regulate the expression of disease-causing genes. The Company's clinical program is focused on evaluating its lead candidate apabetalone (RVX-208) for the treatment of cardiovascular disease and associated comorbidities, and post-COVID-19 conditions. RVX-208 is a small molecule that is a selective bromodomain and extra-terminal (BET) inhibitor. BET bromodomain inhibition is an epigenetic mechanism that can regulate disease-causing genes. RVX-208 is a BET inhibitor selective for the second bromodomain (BD2) within the BET proteins. It partners with EVERSANA, to support the commercialization of RVX-208 for cardiovascular disease, post-COVID-19 conditions, and pulmonary arterial hypertension in Canada and the United States.

TSX:RVX - Post by User

Resverlogix Corp > Screening

<< Previous

Bullboard Posts

Next >>

Comment by narmacon Dec 21, 2021 3:29pm

125 Views

Post# 34251860

RE:RE:RE:Screening

,,,owww,,,,,,my point about the shorts knowing there is no action,,they have made a nice chunk of money off this dog,,,,,,and continue to do so,,,,,cuz they are in the know,,,,,,,,undoubtedly,,when 1,000,000 shares are sold short on a penny stock with BTD from the FDA,,,one has to have special info to make such a play on the short side,,,,,

<< Previous

Bullboard Posts

Next >>

Critical raw materials pioneer drives Europe’s clean energy transition